Collecting Evidence, Reducing the Number of Maternal and Neonatal Mortality
The high number of maternal and neonatal mortality is still a double burden for Indonesia. Based on the Millennium Development Goals (MDGs) data in 2014, every day more than 40 mothers in Indonesia die due to childbirth, or about 305 cases of maternal death per 100,000 live births.
Whereas, the MDGs achievement in 2015 mentions that approximately 80% of mothers in Indonesia have received four antenatal consultations, and roughly 80% of births are performed by professional health workers. On the other hand, neonatal mortality rate has stagnated since 2003 to 2012. So, what really happened?
The cause is still unknown.
Consensus report composed by AIPI and the US National Academy of Sciences (NAS) in 2013, titled Reducing Maternal and Neonatal Mortality in Indonesia, mentioned that Indonesia lacks valid data and information to be able to determine the causes of high maternal and neonatal mortality in Indonesia for several decades. Therefore, AIPI, with the support from USAID, is now seeking to capture data and scientific evidence about the causes of maternal and neonatal mortality as well as various efforts to solve it through the Evidence Summit program to reduce maternal and neonatal mortality in Indonesia, which will last until December 2017. Compared to the implementation of global evidence summit, this program holds more excellence since it embraces more parties, including local governments and provincial health offices.
The launch of the program was held on August 18, 2016, at the Indonesian Ministry of Health office in Jakarta, and involved a range of key stakeholders. Minister of Health Nila F. Moeloek, Sp.M (K) acknowledged that the problem of maternal and neonatal mortality is very complex. Many factors play a role. “The direct cause of maternal mortality is still hemorrhage, eclampsia, and infection,” she said. On the other hand, there are also indirect factors that cause maternal and neonatal mortality, such as poor sanitation, access to clean water, geographical conditions, lack of knowledge on health, and community culture.
Until February 2017, the Evidence Summit team has acquired more than 7,000 literatures reviewed through a systematic review process that netted about 370 eligible evidence on maternal and neonatal mortality. In addition, draft policy recommendations have been arranged to improve the quality of maternal and neonatal health.
“The collected data, among others include program implementation, referral system, quality improvement of health services, and National Health Insurance,” said Convener for Evidence Summit, Prof. Dr. dr. Akmal Taher, Sp.U (K), fellow of Commission for Medical Sciences of AIPI. Scientific evidence from all over Indonesia will be analyzed and discussed with various stakeholders, including governments, health practitioners, universities, and non-governmental organizations.
Evidence Summit is expected to be a good practice for Indonesia in drafting scientific evidence-based policies and involving various stakeholders for the success of national programs, especially in health sector. (*)
Writer: Anggrita Cahyaningtyas